$XCUR The FDA granted it Fast Track designations for AST-008 as well as Orphan Drug Designation. The company announced the issuance of a patent for AST-008 through 2034, as well as positive clinical data for the treatment of patients with Merkel cell carcinoma. Despite some possible fluctuations in the future, it will run hard πŸ’ΈπŸ’Έ
4
4 Likes